Correlation Between Q-value Changes and Progression of Pediatric Keratoconus.

Sponsor
Benha University (Other)
Overall Status
Completed
CT.gov ID
NCT05114928
Collaborator
(none)
9
1
19
14.4

Study Details

Study Description

Brief Summary

Keratoconus is a progressive corneal disease characterized by asymmetric corneal thinning and structural changes in corneal collagen which leads to decrease in visual acuity due to myopic shift, irregular astigmatism or corneal scarring. Early detection of the disease in children aids in halting the progression and improve their quality of life. There is no consensus regarding the progression criteria of the disease, we aimed to assess the changes in corneal asphericity in children after corneal collagen crosslinking and investigate any possible correlation with progression criteria widely used.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Transepithelial Corneal Collagen Cross-linking
  • Diagnostic Test: Scheimpflug camera

Detailed Description

The Keratoconus progression is defined as increasing by 1.0 diopter (D) or more in the maximum keratometry (Kmax), progressive deterioration in Minimal Corneal Thickness is also associated with KC progression, other methods have been investigated to confirm KC progression such as changes in manifest refraction, unaided visual acuity (UAVA), BCVA, posterior keratometric data and higher order aberrations (HOA) which are altered in KC and can aid to confirm disease progression. Q-value (a coefficient of corneal asphericity) reflects the shape of the cornea, its refractive power, and spherical aberration. The mean Q-value in normal cornea is -0.26 ± 0.18, the severity of KC and the Q-value are inversely related.

Mean Q-value in KC at 8mm zone is -0.84 and -1.10 for anterior and posterior corneal surfaces, respectively. Until now, no precise criteria of KC progression especially in cases had undergone previous trans-epithelial corneal collagen cross-linking (TE-CXL) to halt the progression of the disease. In the present study we aimed to analyze the correlation between the changes in Q-value and progression of the KC in children had undergone bilateral TE-CXL.

Study Design

Study Type:
Observational
Actual Enrollment :
9 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Correlation Between Changes in Corneal Asphericity and Progression of Keratoconus in Children
Actual Study Start Date :
Oct 9, 2021
Actual Primary Completion Date :
Oct 25, 2021
Actual Study Completion Date :
Oct 28, 2021

Arms and Interventions

Arm Intervention/Treatment
Progression Group (P-group)

Eyes that showed progression of the disease after trans-epithelial corneal collagen cross-linking during the 5 years of follow-up, (number of eyes = 7 eyes).

Procedure: Transepithelial Corneal Collagen Cross-linking
Bilateral Transepithelial Corneal Collagen Cross-linking was done for all subjects using power of 9mW/cm2 at 55mm from the cornea for 10 minutes, with a total energy of 5.4j/cm2 using the (CCL VARIO, PESCHKE Trade GmbH, Huenenberg Switzerland), in the period between January 2016 to August 2016.
Other Names:
  • TE-CXL
  • Diagnostic Test: Scheimpflug camera
    Pentacam (OCULUS Optikgeräte GmbH, Wetzlar, Germany) was done for all subjects at baseline and annually after TE-CXL till 5 years of follow-up.
    Other Names:
  • Pentacam
  • No Progression Group (NP-group)

    Eyes that showed no progression of the disease after trans-epithelial corneal collagen cross-linking during the 5 years of follow-up, (number of eyes = 11 eyes).

    Procedure: Transepithelial Corneal Collagen Cross-linking
    Bilateral Transepithelial Corneal Collagen Cross-linking was done for all subjects using power of 9mW/cm2 at 55mm from the cornea for 10 minutes, with a total energy of 5.4j/cm2 using the (CCL VARIO, PESCHKE Trade GmbH, Huenenberg Switzerland), in the period between January 2016 to August 2016.
    Other Names:
  • TE-CXL
  • Diagnostic Test: Scheimpflug camera
    Pentacam (OCULUS Optikgeräte GmbH, Wetzlar, Germany) was done for all subjects at baseline and annually after TE-CXL till 5 years of follow-up.
    Other Names:
  • Pentacam
  • Outcome Measures

    Primary Outcome Measures

    1. Changes in corneal asphericity (Q-value) in all subjects. [Baseline and annually after TE-CXL till 5 years of follow-up]

      Evaluate the changes in Q-value after Trans-epithelial corneal collagen cross-linking (TE-CXL) using pentacam.

    Secondary Outcome Measures

    1. Correlation between Q-value changes and disease progression in both groups. [Baseline and annually after TE-CXL till 5 years of follow-up]

      Correlation between the changes in Q-value in different corneal zones and maximum keratometry and minimal corneal thickness in both groups over 5 years of follow-up.

    2. The Q-value as a predictive value in keratoconus progression. [Baseline and annually after TE-CXL till 5 years of follow-up]

      The possibility of using the Q-value parameters as a predictive values to confirm keratoconus progression in children.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    6 Years to 16 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    Children that were diagnosed as bilateral progressive KC (stage I-III, according to amsler classification, Kmax change >1D between 2 scanning with at least 2 months apart), and their age were less than 16 years old at time of TE-CXL, topographic parameters were Kmax 47-60D and MCT more than 400μm.

    Exclusion Criteria:

    Eyes with central corneal scarring, amblyopic eyes, and other corneal pathologies that may alter Pentacam scanning.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Ahmed Abdelshafy Tabl Banhā Benha Egypt 13511

    Sponsors and Collaborators

    • Benha University

    Investigators

    • Principal Investigator: Ahmed A Tabl, MD, Benha University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Ahmed Abdelshafy, Lecturer of Ophthalmology, Benha University
    ClinicalTrials.gov Identifier:
    NCT05114928
    Other Study ID Numbers:
    • RC-10-7-01
    First Posted:
    Nov 10, 2021
    Last Update Posted:
    Nov 10, 2021
    Last Verified:
    Oct 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Ahmed Abdelshafy, Lecturer of Ophthalmology, Benha University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 10, 2021